Screening decreases prostate cancer death: First analysis of the 1988 Quebec prospective randomized controlled trial

Prostate

Volumn 38, Issue 2, 1999, Pages 83-91

  Labrie, Fernand ^a   Candas, Bernard ^a   Dupont, André ^a   Cusan, Lionel ^a   Gomez, Jose Luis ^a   Suburu, Raul E ^a   Diamond, Pierre ^a   Lévesque, Jacques ^a   Belanger, Alain ^a  

^a NONE

Author keywords

Combined androgen blockade; Early treatment of prostate cancer; Prostate cancer screening; PSA; Transrectal ultrasonography

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SCREENING; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; PALPATION; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUEBEC; RECTUM; TIME FACTORS;

EID: 0032894448     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990201)38:2<83::AID-PROS1>3.0.CO;2-B     Document Type: Article

References (41)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-30.
2. Labrie F, Dupont A, Bélanger A, Cusan L, Lacourcière Y, Monfette G, Laberge JG, Emond J, Fazekas AT, Raynaud JP, Husson JM. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 1982;5:267-275.
3. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein DA, Davis MA, Goodman PJ. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-424.
4. Denis L, Carnelro de Moura JL, Bono A, Sylvester R, Whelan R, Newling D, De Pauw M. Goserelin acetate and flutamide vs bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 1993;42:119-129.
5. Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L, Bracken B, Brisset JM, Da Silva FC, Chisholm G, Crawford ED, Debruyne FM, Dijkman GD, Frick J, Goedhals L, Knönagel H, Venner PM. Orchiectomy and Nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993;149:77-83.
6. Caubet JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS, Ross SD. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997;49:71-78.
7. Dijkman GA, Janknegt RA, Dereijke TM, Debruyne FMJ. Long-term efficacy and safety of nilutamide plus castration in advanced prostate-cancer, and the significance of early prostate specific antigen normalization. J Urol 1997;158:160-163.
8. Hoeksema MJ, Law C. Cancer mortality rates fall: a turning point for the nation. J Natl Cancer Inst 1996;88:1706-1707.
9. Killian CS, Emrich LJ, Vargas FP, Yang N, Wang MC, Priore RL, Murphy GP, Chu TM. Relative reliability of five serially measured markers for prognosis of progression in prostate cancer. J Natl Cancer Inst 1986;76:179-185.
10. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, Emond J. Serum prostatic specific antigen (PSA) as prescreening test for prostate cancer. J Urol 1992;147:846-851.
11. Labrie F, Candas B, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996;47:212-217.
12. Lee F, Torp-Pedersen ST, Siders DB, Littrup PJ, McLeary RD. Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma. Radiology 1989;170:609-615.
13. Hanks GE, Asbell SO, Krall JM, Perez CA, Doggett S, Rubin P, Sause WT, Pilepich MV. Outcome for lymph node dissection negative T-1b, T-2 (A-2,B) prostate cancer treated with external beam radiation therapy in RTOG 77-06. Int J Radial Oncol Biol Phys 1991;21:1099-1103.
14. Cooner WH, Mosley BR, Rutherford Jr CL, Beard JH, Pond HS, Terry WJ, Igel TC, Kidd DD. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate-specific antigen. Urology 1990;143:1146-1154.
15. Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, Tetu B, Fradet Y, Candas B. Down-staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with Flutamide and a luteinizing hormone-releasing hormone agonist. Urology 1994; 44:29-37.
16. Laverdiere J, Gomez JL, Cusan L, Suburu R, Diamond P, Lemay M, Candas B, Fortin A, Labrie F. Beneficial effect of combination therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:247-252.
17. Pilepich MV, Krall JM, Al-Saffaf M, John MJ, Dogget RL, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P, Shipley WU, Grignon D, Caplan R, Cox JD. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45:616-623.
18. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
19. Blasko J, Ragde H, Luse R, Sylvester JE, Cavanagh W, Grimm PD. Should brachytherapy be considered a therapeutic option in localized prostate cancer? Urol Clin North Am 1996;23:633-649.
20. Lee F, Littrup PJ, Loft-Christensen L, Kelly Jr BS, McHugh TA, Siders DB, Mitchell AE, Newby JE. Predicted prostate specific antigen results using transrectal ultrasound gland volume. Differentiation of benign prostatic hyperplasia and prostate cancer. Cancer 1992;70(suppl.):211-220.
21. Littrup PJ, Williams CR, Egglin TK, Kane RA. Determination of prostate volume by transrectal US for cancer screening. Part II. Clinical utility of transrectal accuracy of in vivo and in vitro techniques. Radiology 1991;179:45-53.
22. Hodge KK, McNeal JE, Terris MF, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989;142:71-75.
23. Statistics Canada, Health Statistics Division: Life Tables, Canada and Provinces, 1990-1992. Statistics Canada: Ottawa, 1995.
24. Agresti A. Categorial data analysis. In: Wiley Series in Probability and Mathematical Statistics. Applied Probability and Statistics, 0271-6356. New York: John Wiley & Sons, 1990, 558 pp.
25. Barnard GA. A new test for 2 × 2 tables. Nature 1945;156:177.
26. Suissa S, Shuster J. Exact unconditional sample sizes For the 2 × 2 binomial trial. J R Statist Soc Ser A 1985;138:317-327.
27. Breslow NE, Day NE. Statistical methods in cancer research. Volume I - The analysis of case-control studies. IARC Scientific Publications 1980;32:5-338.
28. Cuzick J, Edwards R, Segnan N. Adjusting for non-compliance and contamination in randomized clinical trials. Stat Med 1997; 16:1017-1029.
29. Littrup PJ, Goodman AC, Mettlin CJ. The benefit and cost of prostate cancer early detection. The Investivators of the American Cancer Society-National Prostate Cancer Detection Project. CA Cancer J Clin 1993; 43: 143-149.
30. Hulka BS. Cancer screening. Degrees of proof and practical application. Cancer 1988;62:776-780.
31. Labrie F, Dupont A, Suburu R, Cusan L, Gomez JL, Koutsilieris M, Diamond P, Emond J, Lemay M, Têtu B. Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostatic-specific antigen. Clin Invest Med 1993; 16:425-439.
32. Narod S, Dupont A, Cusan L, Diamond P, Gomez JL, Suburu RE, Labrie F. The impact of family history on early detection of prostate cancer. Nat Med 1995;1:99-101.
33. Sun S, Narod S, Aprikian A, Ghadirian P, Labrie F. Androgen receptor and familial prostate cancer. Nature Medicine 1995;1: 848-849.
34. Kolata G. Prostate cancer consensus hampered by lack of data. Science 1987;236:1626-1627.
35. Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, Grignon D. Phase III trial of androgen suppression using Goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85-31. J Clin Oncol 1997;15: 1013-1021.
36. Labrie F, Cusan L, Gomez JL, Diamond P, Bélanger A. Long-term neoadjuvant and adjuvant combined androgen blockade is needed for efficacy of treatment in localized prostate cancer. Mol Urol 1997;1:253-263.
37. Labrie F, Dupont A, Cusan L, Gomez JL, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lemay M, Têtu B, Emond J, Candas B. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Med 1993;16:499-509.
38. Littrup PJ, Kane RA, Mettlin CJ, Murphy GP, Lee F, Toi A, Badalament R, Babaian R. Cost-effective prostate-cancer detection. Reduction of low-field biopsies. Cancer 1994;74:3146-3158.
39. Aus G, Hugosson J, Norlén L. Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 1995; 154:460-465.
40. Labrie F. Intracrinology and cancer therapy. Science Watch 1994;5:3-8.
41. Labrie F, Cusan L, Gomez JL, Diamond P, Candas B. Combination of screening and preoperative endocrine therapy: the potential for an important decrease in prostate cancer mortality. J Clin Endocrinol Metab 1995; 80: 2002-2013.